AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11573660 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia (BAL)
Number of subjects: 40
Study 9609981 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified phenolic glycolipid (PGL‐1) ELISA in leprosy patients
Number of subjects: 698
Study 9609981 — intervention group
Group type: COMPARATOR
Intervention: Purified phenolic glycolipid (PGL‐1) ELISA in non-leprosy cases
Number of subjects: 698
Study 7923660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 641
Study 7923660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study 3246461 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan supplementation
Number of subjects: 12
Study 3246461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30869958 — intervention group
Group type: EXPERIMENTAL
Intervention: Faking good
Number of subjects: 233
Study 30869958 — intervention group
Group type: EXPERIMENTAL
Intervention: Faking bad
Number of subjects: 233
Study 30869958 — intervention group
Group type: COMPARATOR
Intervention: Control condition (honest/honest)
Number of subjects: 233
Study 30869958 — intervention group
Group type: EXPERIMENTAL
Intervention: Social desirability scales
Number of subjects: 233
Study 27922194 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 20
Study 27922194 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (200 mg)
Number of subjects: 20
Study 27922194 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (50 mg)
Number of subjects: 20
Study 27922194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25193374 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (iCBT)
Number of subjects: 110
Study 23999454 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 0
Study 23999454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21454913 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish portion snus
Number of subjects: 14
Study 21454913 — intervention group
Group type: COMPARATOR
Intervention: 4 mg nicotine polacrilex chewing gum
Number of subjects: 14
Study 18266665 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 26
Study 18266665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17335542 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1600 microg Pulmicort Turbohaler)
Number of subjects: 10
Study 17335542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Placebo Turbohaler)
Number of subjects: 10
Study 14763919 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-stimulated glucose uptake (ISGU) in FDR
Number of subjects: 20
Study 14763919 — intervention group
Group type: COMPARATOR
Intervention: Insulin-stimulated glucose uptake (ISGU) in controls
Number of subjects: 20
Study 14763919 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue in FDR
Number of subjects: 20
Study 14763919 — intervention group
Group type: COMPARATOR
Intervention: Visceral adipose tissue in controls
Number of subjects: 20
Study 14763919 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2 max in FDR
Number of subjects: 20
Study 14763919 — intervention group
Group type: COMPARATOR
Intervention: VO2 max in controls
Number of subjects: 20
Study 14763919 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline palmitate appearance in FDR
Number of subjects: 20
Study 14763919 — intervention group
Group type: COMPARATOR
Intervention: Baseline palmitate appearance in controls
Number of subjects: 20
Study 14763919 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h u-cortisol/creatinine ratio in FDR
Number of subjects: 20
Study 14763919 — intervention group
Group type: COMPARATOR
Intervention: 24 h u-cortisol/creatinine ratio in controls
Number of subjects: 20
Study 11346340 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpalmoplantar pure epidermal sheet grafts (n = 14)
Number of subjects: 48
Study 11346340 — intervention group
Group type: COMPARATOR
Intervention: Nonpalmoplantar donor site skin grafts (n = 17)
Number of subjects: 48
Study 11346340 — intervention group
Group type: COMPARATOR
Intervention: Palmoplantar donor site skin grafts (n = 17)
Number of subjects: 48
Study 9215845 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 150 U/kg three times a week
Number of subjects: 62
Study 9215845 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 62
Study 7584276 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity decision to familiar full names
Number of subjects: 0
Study 7584276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical decision
Number of subjects: 0
Study 7584276 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeating the same decision during initial and test phases
Number of subjects: 0
Study 3667393 — intervention group
Group type: EXPERIMENTAL
Intervention: Female physicians
Number of subjects: 112
Study 3667393 — intervention group
Group type: EXPERIMENTAL
Intervention: Male physicians
Number of subjects: 112
Study 31317322 — intervention group
Group type: EXPERIMENTAL
Intervention: smartphone‐enabled otoscope
Number of subjects: 60
Study 31317322 — intervention group
Group type: COMPARATOR
Intervention: conventional otoscope
Number of subjects: 60
Study 28846831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cofact
Number of subjects: 15
Study 28846831 — intervention group
Group type: EXPERIMENTAL
Intervention: Beriplex
Number of subjects: 15
Study 28846831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study 28846831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cofact and Beriplex
Number of subjects: 15
Study 26255511 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) intervention with stimulation of dense-disperse wave (10 Hz/50 Hz) at Tianshu (ST 25) and Zusanli (ST 36), 0.1 to 1.0 mA, once daily for 5 times a week for 2 weeks, then 2 times a week for 2 weeks.
Number of subjects: 340
Study 26255511 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) intervention
Number of subjects: 340
Study 26255511 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 340
Study 24015975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ti (titanium) 4.1 mm diameter implants
Number of subjects: 40
Study 24015975 — intervention group
Group type: EXPERIMENTAL
Intervention: TiZr (titanium-zirconium) 3.3 mm diameter implants
Number of subjects: 40
Study 24015975 — intervention group
Group type: COMPARATOR
Intervention: Both Ti and TiZr implants
Number of subjects: 40
Study 21677073 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient beverage (250 mL/d including vitamin A, iron, and zinc)
Number of subjects: 566
Study 21677073 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (isoenergetic)
Number of subjects: 566
Study 19699832 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted educational lessons based on the Medicine Wheel Model for Nutrition (6 lessons over 6 months)
Number of subjects: 114
Study 19699832 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary education from personal providers
Number of subjects: 114
Study 16125417 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Training (MT) alone
Number of subjects: 11
Study 16125417 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation (AO) alone
Number of subjects: 11
Study 16125417 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Motor Training and Action Observation (MT + AO)
Number of subjects: 11
Study 19780243 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0
Study 19780243 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy after concurrent chemoradiotherapy
Number of subjects: 0
Study 19780243 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor inhibitors (tyrosine kinase inhibitors or monoclonal antibodies)
Number of subjects: 0
Study 11852812 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser biostimulation (810 nm, 4 J/cm2)
Number of subjects: 49
Study 11852812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (quasi-laserotherapy)
Number of subjects: 49
Study 11852812 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 49
Study 9932083 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan (350 mg/m2 administered over 90 minutes every 3 weeks)
Number of subjects: 539
Study 8185450 — intervention group
Group type: EXPERIMENTAL
Intervention: High resistance exercise program
Number of subjects: 16
Study 8185450 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects (CTL)
Number of subjects: 16
Study 3063534 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolipram 0.50 mg orally t.i.d. for the first three days, then 0.75 mg orally t.i.d. until day 28
Number of subjects: 0
Study 3063534 — intervention group
Group type: COMPARATOR
Intervention: Desipramine 25 mg orally t.i.d. for the first three days, then 50 mg orally t.i.d. until day 28
Number of subjects: 0
Study 31347193 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation (1.064 mm wavelength diode laser, 3.5 W output power, 1,100-1,500 J, 5-8 min/illumination, one or two fibers/session)
Number of subjects: 34
Study 31347193 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy subgroup (n = 14, mean 599.9 ± 136.5 J/ml)
Number of subjects: 34
Study 31347193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy subgroup (n = 7, mean 240.2 ± 74.6 J/ml)
Number of subjects: 34
Study 31347193 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinical follow up)
Number of subjects: 34
Study 30818339 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antiparasitic therapy during pregnancy
Number of subjects: 576
Study 30818339 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-valent S. pneumoniae conjugate vaccine and pentavalent vaccine
Number of subjects: 576
Study 29634701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.03%) eye ointment BD
Number of subjects: 46
Study 29634701 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (0.05%) eyedrops QID
Number of subjects: 46
Study 26912081 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported service use
Number of subjects: 433
Study 26492775 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin, propranolol with monopril and PCI
Number of subjects: 63
Study 26492775 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylase (tenakteplaza) and propranolol, monopril followed by PCI after 1 day
Number of subjects: 63
Study 26492775 — intervention group
Group type: COMPARATOR
Intervention: PCI only
Number of subjects: 63
Study 22710021 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statin
Number of subjects: 213
Study 22710021 — intervention group
Group type: COMPARATOR
Intervention: Low-dose statin plus ezetimibe
Number of subjects: 213
Study 19382492 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC) nasal packing
Number of subjects: 40
Study 19382492 — intervention group
Group type: COMPARATOR
Intervention: Unpacked side (control)
Number of subjects: 40
Study 19382492 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC mesh
Number of subjects: 40
Study 19382492 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC gel
Number of subjects: 40
Study 17786889 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Stroke Massage
Number of subjects: 32
Study 17786889 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 32
Study 14980279 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal dexamethasone
Number of subjects: 0
Study 14980279 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids used early (<2 wk)
Number of subjects: 0
Study 14980279 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids used late (>2 wk)
Number of subjects: 0
Study 14980279 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids
Number of subjects: 0
Study 14980279 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 12513901 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Number of subjects: 0
Study 12513901 — intervention group
Group type: COMPARATOR
Intervention: Self-administered therapy
Number of subjects: 0
Study 9495601 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg/day
Number of subjects: 281
Study 9495601 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 281
Study 7701064 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric patients with religious commitment
Number of subjects: 44
Study 7701064 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 44
Study 2515967 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg nitroglycerin
Number of subjects: 40
Study 2515967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 356868 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine (in addition to diazepam)
Number of subjects: 0
Study 356868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in addition to diazepam)
Number of subjects: 0
Study 356868 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0
Study 30614468 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole after aromatase inhibitor-based therapy
Number of subjects: 0
Study 30614468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28935147 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant wheat starch (RWS)
Number of subjects: 27
Study 28935147 — intervention group
Group type: COMPARATOR
Intervention: Standard wheat flour (SWF)
Number of subjects: 27
Study 26194634 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal cross-linking treatment (15 eyes)
Number of subjects: 29
Study 26194634 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 eyes)
Number of subjects: 29
Study 22963506 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 12.5 mg
Number of subjects: 186
Study 22963506 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 186
Study 22963506 — intervention group
Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 186
Study 22963506 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5 mg and 25 mg)
Number of subjects: 186
Study 22157475 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial (TR) approach
Number of subjects: 3340
Study 22157475 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral (TF) approach
Number of subjects: 3340
Study 19558610 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg twice daily)
Number of subjects: 100
Study 19558610 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg twice daily) in statin users (n = 22)
Number of subjects: 100
Study 16741303 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-derived input functions (IDIFs) from the ascending aorta
Number of subjects: 76
Study 16741303 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-derived input functions (IDIFs) from the left ventricle
Number of subjects: 76
Study 16741303 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-derived input functions (IDIFs) from the abdominal aorta
Number of subjects: 76
Study 15636668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine combined with an educational intervention (printed information and explanation about OAB, medication use, and behavioral treatments)
Number of subjects: 0
Study 15636668 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine alone (no intervention)
Number of subjects: 0
Study 15636668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine combined with an educational intervention
Number of subjects: 0
Study 11387573 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation through a microcomputer every night for 8 hours.
Number of subjects: 40
Study 11387573 — intervention group
Group type: COMPARATOR
Intervention: Placebo group using identical functioning units that delivered no current.
Number of subjects: 40
Study 11387573 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation (compliant patients).
Number of subjects: 40
Study 11387573 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation (noncompliant patients).
Number of subjects: 40
Study 11387573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (compliant patients).
Number of subjects: 40
Study 11387573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (noncompliant patients).
Number of subjects: 40
Study 9404828 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-induced extracorporeal low-density lipoprotein (LDL) precipitation (HELP)
Number of subjects: 0
Study 8121866 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40
Study 8121866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8121866 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil and Placebo
Number of subjects: 40
Study 3465581 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg/day
Number of subjects: 83
Study 3465581 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 1500 ug/day
Number of subjects: 83
Study 3465581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 29659529 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE)
Number of subjects: 9
Study 29659529 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE)
Number of subjects: 9
Study 29659529 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study 27727055 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate motion (IM)
Number of subjects: 60
Study 27727055 — intervention group
Group type: COMPARATOR
Intervention: Delayed motion (DM)
Number of subjects: 60
Study 24177413 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinical advice plus free-of-charge access to a group-based adaption of the DPP offered by the YMCA
Number of subjects: 509
Study 24177413 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical advice alone
Number of subjects: 509
Study 23091246 — intervention group
Group type: EXPERIMENTAL
Intervention: TRA-8 alone
Number of subjects: 30
Study 23091246 — intervention group
Group type: EXPERIMENTAL
Intervention: TRA-8 + Abraxane
Number of subjects: 30
Study 23091246 — intervention group
Group type: EXPERIMENTAL
Intervention: Abraxane (paclitaxel) alone
Number of subjects: 30
Study 23091246 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 15833948 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (≥ 45 minutes of moderate-intensity aerobic activity 5 days/week)
Number of subjects: 173
Study 15833948 — intervention group
Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 173
Study 12015810 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participation in musical activity (30-minute session playing percussive instruments and singing)
Number of subjects: 33
Study 12015810 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive participation in musical activity (30-minute session listening to live music)
Number of subjects: 33
Study 12015810 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 33
Study 10624252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home care settings
Number of subjects: 0
Study 10624252 — intervention group
Group type: COMPARATOR
Intervention: Community hospital care settings
Number of subjects: 0
Study 10624252 — intervention group
Group type: COMPARATOR
Intervention: Patients on hypnotic medication
Number of subjects: 0
Study 10624252 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not on hypnotic medication
Number of subjects: 0
Study 7793870 — intervention group
Group type: EXPERIMENTAL
Intervention: LYO (lyophilized RSVIG)
Number of subjects: 30
Study 7793870 — intervention group
Group type: EXPERIMENTAL
Intervention: LYO-VI (lyophilized RSVIG with viral inactivation)
Number of subjects: 30
Study 7793870 — intervention group
Group type: EXPERIMENTAL
Intervention: LIQ-VI (liquid RSVIG with viral inactivation)
Number of subjects: 30
Study 2162239 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (120 mg/m2, days 1‐3)
Number of subjects: 216
Study 2162239 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide plus high-dose cisplatin (60 mg/m2, days 1‐2)
Number of subjects: 216
Study 2162239 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 216
Study 2162239 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide plus high-dose cisplatin
Number of subjects: 216
Study 469108 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (low dose equivalent to one cup of coffee)
Number of subjects: 17
Study 469108 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (high dose equivalent to three cups of coffee)
Number of subjects: 17
Study 469108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29869961 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Mammography plus Digital Breast Tomosynthesis (DBT+DM)
Number of subjects: 19560
Study 29869961 — intervention group
Group type: COMPARATOR
Intervention: Digital Mammography (DM)
Number of subjects: 19560
Study 28468749 — intervention group
Group type: EXPERIMENTAL
Intervention: EDGE (digital health system)
Number of subjects: 166
Study 25731582 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonak BTE with NLFC
Number of subjects: 11
Study 25731582 — intervention group
Group type: COMPARATOR
Intervention: Phonak BTE without NLFC
Number of subjects: 11
Study 25731582 — intervention group
Group type: COMPARATOR
Intervention: Oticon BTE with wideband response
Number of subjects: 11
Study 25731582 — intervention group
Group type: EXPERIMENTAL
Intervention: NLFC condition
Number of subjects: 11